Psychedelic- and Substance-Assisted Therapies in Global Mental Health: Bridging Cultures, Evidence, and Access.
Brain and Behavior February 1, 2026 DOI: 10.1002/brb3.71265 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Citations | 1 |
| Key points | Argues that equitable use of psychedelic- and substance-assisted therapies in global mental health requires culturally grounded, ethically robust, and context-sensitive pathways rather than uncritical expansion. |
Abstract
Psychedelic- and substance-assisted therapies, including MDMA, psilocybin, and ketamine, are gaining attention for conditions such as PTSD and depression, yet their development and implementation remain largely concentrated in high-income settings. This graphical abstract summarizes the central argument of the commentary: while these interventions may hold relevance for global mental health, particularly in conflict-affected and humanitarian contexts, their equitable use is constrained by cultural, ethical, regulatory, and resource-related challenges. Responsible implementation requires culturally grounded, ethically robust, and context-sensitive pathways rather than uncritical expansion.
Citations in the library
Cited by 1
Cites 6
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine. Culture, Medicine, and Psychiatry December 1, 2022
- Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial EClinicalMedicine March 14, 2025
and 1 more in the library